Suomi - suomi - Fimea (Suomen lääkevirasto)

tabletti, päällystetty - n05cm09 valerianae root [näytä kaikki saman ryhmän lääkevalmisteet] - itsehoito - 21.06.2007

Suomi - suomi - Fimea (Suomen lääkevirasto)

medica - atropini sulfas,uute, neste valerianae,phenobarbitalum - tabletti - atropiini ja psyykenlääke

Suomi - suomi - Fimea (Suomen lääkevirasto)

bayer ag - atropini sulfas,papaverini hydrochloridum,phenobarbitalum,extractum fluidum valerianae - tabletti - muut psyykenlääkkeitä sisältävät yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion oyj - methylpentynolum,uute, neste valerianae,camphora - tipat - metyylipentynoli, yhdistelmävalmisteet

Suomi - suomi - Fimea (Suomen lääkevirasto)

medica - phenobarbitalum,papaverini hydrochloridum,extractum fluidum valerianae,atropini sulfas - tabletti - muut psyykenlääkkeitä sisältävät yhdistelmävalmisteet

Euroopan unioni - suomi - EMA (European Medicines Agency)

sanofi winthrop industrie - dupilumab - dermatitis, atopic; prurigo; esophageal diseases; asthma; sinusitis - dermatiittiautia lukuun ottamatta kortikosteroideja - atopic dermatitisadults and adolescentsdupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. children 6 months to 11 years of agedupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy. asthmaadults and adolescentsdupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), see section 5. 1, who are inadequately controlled with high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. children 6 to 11 years of agedupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (feno), who are inadequately controlled with medium to high dose inhaled corticosteroids (ics) plus another medicinal product for maintenance treatment. chronic rhinosinusitis with nasal polyposis (crswnp)dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. prurigo nodularis (pn)dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (pn) who are candidates for systemic therapy. eosinophilic esophagitis (eoe)dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.

Suomi - suomi - Fimea (Suomen lääkevirasto)

soho flordis uk limites - melissae leaf extract methanolum paksu,valerianae root pura hengen paksu,melissae leaf extract methanolum kuiva,valerianae root pura henki kuiva - tabletti, päällystetty - valerianae radix

Suomi - suomi - Fimea (Suomen lääkevirasto)

tabletti, päällystetty - n05cm09 valerian root [näytä works saman ryhmän lääkevalmisteet] - itsehoito - 08.07.2017

Euroopan unioni - suomi - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - sucroferric oxyhydroxide - hyperphosphatemia; renal dialysis - lääkkeitä hoitoon hyperkalemia ja hyperphosphatemia - velphoro on tarkoitettu fosforin seerumin aikuisten krooninen munuaisten saannissa (ckd) ohjausobjektiin hemodialyysiin (hd) tai vatsakalvodialyysia (pd). velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with ckd stages 4-5 (defined by a glomerular filtration rate.

Euroopan unioni - suomi - EMA (European Medicines Agency)

nova laboratories ireland limited - spironolaktoni - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 ja 5.